AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: place holder - do not post
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 500mg
Description: A single dose of metformin 500 mg tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single dose of 50 mg sitagliptin tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 1000 mg
Description: A single dose of metformin 1000 mg tablet
Study NCT00961480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 850 mg
Description: A single dose of metformin 850 mg tablet
Study NCT04556903 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training
Description: First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I
Study NCT04556903 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: modified constrained induce movement therapy
Description: BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~* Block placement- 10minutes~* Peg targeting- 10 minutes~* Peg inversion-10miutes~* Transferring objects- 10minutes
Study NCT00106587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA
Study NCT00106587 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: paclitaxel coated balloon catheter (device with drug)
Study NCT01014143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Half mouth toothbrushing twice a day for four days.
Study NCT01014143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine digluconate
Description: Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
Study NCT01014143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride, triclosan
Description: Half mouth Brushing twice daily
Study NCT03053518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Description: A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
Study NCT03566225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: Induction drug
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs.
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section.
Study NCT03053518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LifeStyle
Description: Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
Study NCT03053518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeStyle
Description: Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other TB drugs
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other TB drugs
Description: Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant dexamethasone
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Study NCT02169882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant dexamethasone
Description: Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
Study NCT02601755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanCope app and website
Description: In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources.
Study NCT02601755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention control group
Description: The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies.
Study NCT01328015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin 5 mg pills
Description: ½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.
Study NCT01328015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin 5 mg pills
Description: ½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preop acetaminophen IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preop acetaminophen IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preop orphenadrine IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preop orphenadrine IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop oral oxycodone & acetaminophen
Study NCT01668420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermal stimulation
Description: hot and cold/warm and cool pads applying.
Study NCT01668420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thermal stimulation
Description: hot and cold/warm and cool pads applying.
Study NCT03277937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiography in EUS-injection of coils + CYA
Description: Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop hydromorphone IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop hydromorphone IV
Study NCT03630393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum Pressure 6 mmHg
Description: A pneumoperitoneum insufflation pressure of 6 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
Study NCT03630393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum Pressure 15 mmHg
Description: A pneumoperitoneum insufflation pressure of 15 mmHg will be used during robotic assisted laparoscopic prostatectomy (RALP).
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postop oral orphenadrine
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop oral oxycodone
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop acetaminophen IV
Study NCT02449369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postop orphenadrine IV
Study NCT02275975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study NCT02275975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Study NCT05110170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01005
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Study NCT05110170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX® 3.6 mg
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Study NCT04708353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsule (vitamin c)
Description: the patient will receive one placebo capsule (vitamin c) once one hour before the operation
Study NCT04708353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group pregabalin 150
Description: the patient will receive one capsule of pregabalin 150 mg once one hour before the operation
Study NCT04708353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group pregabalin 300
Description: the patient will receive one capsule of pregabalin 300 mg once one hour before the operation
Study NCT00776880 — intervention group
Intervention type: OTHER
Intervention: ASA scale
Description: ASA scale evaluation before operation
Study NCT00776880 — intervention group
Intervention type: OTHER
Intervention: PPS scale
Description: PPS scale evaluation before operation
Study NCT01980953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Phase III Tablet
Description: Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
Study NCT01980953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Tablet
Description: Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
Study NCT04100278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care diabetes management
Description: After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
Study NCT01073787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 10 ml/kg of normal saline will be administered over 30 minutes
Study NCT01073787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 10 ml/kg of normal saline will be administered over 30 minutes
Study NCT04018677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of TOGETHERCare app
Description: TOGETHERCare (Medable Inc.) is a mobile software application on a smart software system that informal caregivers can use to develop and implement home-based care for cancer patients/survivors. It is intended to improve the care experience by helping to alleviate the cancer care-giving burden and facilitate communication with patients' healthcare teams by centering the conversation around a care plan.
Study NCT04495075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visuomotor Therapy
Description: The use of visual feedback informing internal physiological processes, such as muscle activation, torque, and joint position, has been termed visuomotor therapy. Visuomotor therapy encompasses completion of sub-maximal motor control tasks accompanying real-time visual biofeedback.
Study NCT04495075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Passive Motion
Description: The knee is passively moved through a range of motion.
Study NCT00712140 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV
Study NCT00712140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00712140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parenteral chemotherapy
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab
Study NCT00712140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parenteral chemotherapy
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab
Study NCT04040790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens without a passive artificial iris
Description: Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
Study NCT04040790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens with a passive artificial iris with low contrast (<1:5)
Description: Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
Study NCT04040790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral contact lens with a passive artificial iris with high contrast (>1:5)
Description: Participants wear a scleral contact lens with a low contrast (\<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
Study NCT04040790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropicamide and phenylephrine
Description: Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
Study NCT03550391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
Study NCT03550391 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal-avoidant (HA-WBRT) Radiotherapy
Description: 30Gy in 10 fractions
Study NCT03550391 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: 18-20 or 22 Gy in single fraction
Study NCT01076647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Will be injected subcutaneously (under the skin) once daily three times weekly.
Study NCT01076647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
Study NCT02133209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
Study NCT02133209 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management for Headaches
Description: Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
Study NCT01980953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032 Capsule
Description: Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
Study NCT03964207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® (T1)
Description: inhalation solution
Study NCT03964207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Handihaler® (T2)
Description: Inhalation Powder
Study NCT05190614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The biotype of gingiva
Description: The biotype of gingival was determined by periodontal probe.
Study NCT03481543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In-line nebulization through NIV mask
Description: In-line nebulization will be given through NIV circuit.
Study NCT03481543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Off-NIV nebulization
Description: Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
Study NCT01563159 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
Study NCT02570087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chronic total coronary occlusion percutaneous intervention
Description: Percutaneous intervention of chronic total coronary occlusion with stent implantation
Study NCT04491552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patients monitored with TruGraf and TRAC testing
Description: This is an observational study there are no protocol mandated interventions. TruGraf and TRAC results will be utilized in conjunction with standard of care assessments to determine patient management.
Study NCT03597802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise at workplace - Three times per week
Description: The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
Study NCT00942305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Subjects received their first dose of study drug of brincidofovir (BCV) within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.
Study NCT00942305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received their first dose of study drug within 30 (+5) days post-transplant and were treated through Week 13 post-transplant.~Matching placebo administered for each cohort.
Study NCT01081600 — intervention group
Intervention type: OTHER
Intervention: Imaging with 89Zr-trastuzumab PET
Description: Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
Study NCT00800553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: 5mg o.m. p.o. for approx. 2 weeks
Study NCT00800553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg of placebo for approx. 2 weeks